Efficacy and safety of intravitreal dexamethasone implant in treatment na?ve eyes with diabetic macular edema: Real world experience

摘要

Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant in treatment na?ve eyes with diabetic macular edema (DME). Methods: A retrospective analysis of treatment na?ve eyes with DME which received intravitreal dexamethasone implant between January 2016 and March 2018 was done. Demographic details of the patients, ocular examination findings at baseline and on follow up visits were noted. Morphological features of DME and central macular thickness were noted on optical coherence tomography at each visit. The details regarding additional treatment for macular edema on follow up were noted. Results: Sixty five eyes were included in the study. The mean age was 59.14?±?9.59?years. The follow up ranged from 6 to 48?months. Psuedophakic eyes showed visual improvement whereas the phakic eyes showed stable vision. The central foveal thickness showed significant reduction ( p ?=?0.05) in all the eyes. The best corrected visual acuity at final follow up (+0.65?logMAR) was slightly less as compared to baseline (+0.62?logMAR). Retreatment was needed in 37% eyes and antiglaucoma medications in 8% eyes. Cataract progression was noted in 24 eyes (37%); 17 eyes (26.1%) underwent surgery. Notably, 27 eyes (41.5%) had some degree of macular ischemia at baseline. And five eyes (7.7%) showed progression of retinopathy leading to vitreous hemorrhage. Conclusion: Dexamethasone implant is helpful in reducing the macular thickness and stabilizing the vision in treatment na?ve DME; requiring less number of treatment sessions. However, it does not prevent progression of diabetic retinopathy. The visual improvement may be affected by cataract and macular ischemia.